Off-label use of drug-eluting stents: Assessing the risk: Commentary

Nature Clinical Practice Cardiovascular Medicine

Volumn 4, Issue 11, 2007, Pages 594-595

  Mehran, Roxana ^a   Dangas, George D ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; RAPAMYCIN;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CREATINE KINASE BLOOD LEVEL; DRUG ELUTING STENT; EVIDENCE BASED MEDICINE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; OUTCOME ASSESSMENT; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; THROMBOSIS; TREATMENT INDICATION;

EID: 35648977056     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0987     Document Type: Short Survey

References (5)

1. Spaulding C et al. (2007) A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356: 989-997
2. Stone GW et al. (2007) Safety and efficacy of sirolimusand paclitaxel-eluting coronary stents. N Engl J Med 356: 998-1008
3. Serruys PW et al. (2006) Coronary-artery stents. N Engl J Med 354:483-495
4. Cordis (online April 2003) Instructions for use CYPHER™ Sirolimus-eluting Coronary Stent on RAFTORTM Over-the-Wire Delivery Systom and CYPHER™ Sirolimuseluting Coronary Stent on RAPTORRAIL® Rapid Exchange Delivery System [http:/www.fda.gov/cdrh/PDF2/p020026c.pdf] (accessed 31 July 2007)
5. Beohar N et al. (2007) Outcomes and complications associated with off-label and Untested use of drug-eluting stents. JAMA 297: 1992-2000